Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples
Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the
largest comprehensive cancer centre in Europe. In addition to an in-house drug development
program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In
order to investigate the optimal use of novel molecularly targeted agents, access to
clinical tumour samples is needed in order to determine which particular cancer type
expresses a molecular "signature" that may indicate potential therapeutic utility.
Understanding such signatures should accelerate the registration of new drugs for routine
cancer therapy; offering the potential of selecting those patients with tumour types most
likely to benefit from therapy. Furthermore, new insights into disease biology may be
Main research question/ objective - Are there features of primary melanoma or lymph node
metastases that predict subsequent clinical outcome better than existing markers?
Observational Model: Case Control, Time Perspective: Retrospective
Given that the nature of the research is qualitative, there is no primary outcome measure.
Professor Martin Gore
Royal Marsden NHS Foundation Trust
United Kingdom: Research Ethics Committee